Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, First-In-Human, Multicenter, Open-Label Study of TT-00420, Administered Orally in Adult Patients With Advanced Solid Tumors and Triple Negative Breast Cancers

Trial Profile

A Phase I, First-In-Human, Multicenter, Open-Label Study of TT-00420, Administered Orally in Adult Patients With Advanced Solid Tumors and Triple Negative Breast Cancers

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tinengotinib (Primary)
  • Indications Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Colon cancer; Head and neck cancer; HER2 negative breast cancer; Mesothelioma; Peritoneal cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man
  • Sponsors TransThera Biosciences
  • Most Recent Events

    • 28 Dec 2023 Planned End Date changed from 30 Dec 2021 to 28 Feb 2024.
    • 07 Dec 2023 According to a TransThera Biosciences media release, data from this study were presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) annual meeting.
    • 07 Dec 2023 Results (N=36, cut off : October 1, 2023) presented in a TransThera Biosciences media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top